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Background {#ehf212642-sec-0004}
==========

After discharge from heart failure (HF) hospitalization, patients are at an unacceptably high risk of death and recurrent hospitalization for HF. Patients with chronic HF and reduced ejection fraction (HFrEF) should receive renin angiotensin aldosterone system inhibitors (RAASi) to improve survival and diuretic therapy to alleviate congestion‐related symptoms. However, in daily practice, patients receive suboptimal doses of RAASi mostly due to concerns of worsening renal function (WRF) and hyperkalaemia.[1](#ehf212642-bib-0001){ref-type="ref"} In addition, undiagnosed residual congestion is a major driver of post‐discharge early readmission.[2](#ehf212642-bib-0002){ref-type="ref"}

Instantaneous plasma volume estimated from haemoglobin/haematocrit[3](#ehf212642-bib-0003){ref-type="ref"}, [4](#ehf212642-bib-0004){ref-type="ref"} and its changes[5](#ehf212642-bib-0005){ref-type="ref"} are indicative of congestion status[6](#ehf212642-bib-0006){ref-type="ref"}, [7](#ehf212642-bib-0007){ref-type="ref"} and are associated with prognosis in acute or chronic HF.[8](#ehf212642-bib-0008){ref-type="ref"}, [9](#ehf212642-bib-0009){ref-type="ref"}, [10](#ehf212642-bib-0010){ref-type="ref"} We hypothesized that daily post‐discharge home monitoring of plasma volume, blood potassium, and estimated glomerular filtration rate (eGFR) could identify electrolyte and cardiorenal changes that could benefit outpatient optimization of diuretic and RAASi therapy.

Aims {#ehf212642-sec-0005}
====

The aim of this study is to assess the daily variations in estimated plasma volume (ePV), blood potassium, and eGFR after discharge from hospitalization for decompensated heart failure, using a home‐based finger capillary blood measurement 5 days a week during 2 months post‐discharge and an approved bioassay device (ABOTT i‐STAT) (<http://ClinicalTrials.gov>: NCT01655134).

Methods {#ehf212642-sec-0006}
=======

The study was performed in a single tertiary referral centre, sponsored and funded by the University Hospital (CHRU) of Nancy, France. The protocol was approved by the Comité de Protection de Personnes Est‐III prior to study initiation. All patients provided written informed consent before participating in the study. Assuming 8% of nonanalysable observations, a sample size of 20 patients was required to ensure a 0.5 SD accuracy for daily measurements and a corresponding 0.2 mmol/L accuracy for serum potassium.[5](#ehf212642-bib-0005){ref-type="ref"}

The capillary blood samples were drawn by study nurses at home (7--12 am). No data were communicated to the treating physician except in instances where blood potassium was ≥5.8 mmol/L. Haematocrit was determined using conductometry by i‐STAT, which provides a calculated haemoglobin result as follows:

haemoglobin (g/dL) = haematocrit (**%**) × **0**.34, which was shown to be well correlated with the reference methods over a broad range of values between 6 and 16 g/dL.[11](#ehf212642-bib-0011){ref-type="ref"}

Estimated plasma volume[12](#ehf212642-bib-0012){ref-type="ref"} and its changes[5](#ehf212642-bib-0005){ref-type="ref"} were computed as previously described. A threshold of 5.5 mL/g Hb at discharge was deemed clinically relevant since associated with both congestion features and poor clinical outcomes.[9](#ehf212642-bib-0009){ref-type="ref"}

Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration formula.[13](#ehf212642-bib-0013){ref-type="ref"}

Biological events are described as episodes (mean number of separate sequences with values persistently above or below a given threshold, i.e., hyperkalaemia \>5.5 mmol/L or \>5 mmol/L, hypokalaemia \<4 or 3.5 mmol/L, WRF (drop in eGFR) \>20% or 30%, ePV increase \>10% or 15% or above 5.5 mL/g Hb) and mean number of measurements per episode.

Results {#ehf212642-sec-0007}
=======

Among the 15 home‐monitored patients, two patients died (one suddenly), and one was readmitted for ischaemic acute pulmonary oedema, with a subsequent acute coronary syndrome, and thus did not have a complete 2‐month follow‐up (see study flowchart in online supplement).

Baseline patient characteristics are presented in *Table* [1](#ehf212642-tbl-0001){ref-type="table"}. Individual follow‐up data and post‐discharge treatment changes are presented in *Tables* [2](#ehf212642-tbl-0002){ref-type="table"} and [3](#ehf212642-tbl-0003){ref-type="table"}. The 5‐day‐a‐week biological home monitoring (*Figure* [*1*](#ehf212642-fig-0001){ref-type="fig"}) enabled documenting a number of hyperkalaemia, hypokalaemia, WRF and recongestion episodes (*Table* [4](#ehf212642-tbl-0004){ref-type="table"}).

###### 

Baseline characteristics

  Characteristics                *N*   Mean ± SD or *n* (%)   Median (Q1−Q3)      Range
  ------------------------------ ----- ---------------------- ------------------- ------------
  Demography                                                                      
  Age (years)                    15    71 ± 10                71 (68--76)         38--84
  Male gender                    15    11 (73%)                                   
  Physical examination                                                            
  BMI (kg/m^2^)                  15    28.3 ± 5.7             28.1 (24.4--33.0)   17.6--36.7
  Blood pressure                                                                  
  systolic (mmHg)                15    117 ± 14               117 (107--126)      95--145
  diastolic (mmHg)               15    70 ± 11                67 (63--81)         51--89
  MAP (mmHg)                     15    86 ± 11                85 (78--95)         66--108
  Cardiac examination                                                             
  LVEF (%)                       15    31 ± 9                 30 (25--35)         10--45
  Sinus rhythm                   15    7 (47%)                                    
  Pacing                         15    2 (13%)                                    
  ICD                            15    5 (33%)                                    
  NYHA class                     15                                               
  I                                    1 (7%)                                     
  II                                   6 (40%)                                    
  III                                  7 (47%)                                    
  IV                                   1 (7%)                                     
  Acute coronary syndrome                                                         
  Previous history                                                                
  Ischaemic cardiopathy          15    7 (47%)                                    
  Hypertension                   15    7 (47%)                                    
  COPD                           15    2 (13%)                                    
  Neoplasia                      15    5 (33%)                                    
  Risk factors                                                                    
  Smoker (past or current)       15    6 (40%)                                    
  Dyslipidaemia                  15    6 (40%)                                    
  Diabetes                       15    8 (53%)                                    
  Biochemistry                                                                    
  Kalaemia (mmol/L)              15    4.5 ± 0.6              4.4 (3.9--4.9)      3.8--5.8
  eGFR (mL/min/1.73 m^2^)        15    60 ± 17                61 (47--78)         27--87
  ePV (mL/g Hb)                  15    4.6 ± 1.3              4.4 (3.5--5.0)      2.8--7.9
  Myocardial stretch biomarker                                                    
  BNP (pg/mL)                    15    588 ± 405              432 (258--994)      94--1286

BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate (CKD‐EPI formula); ePV, estimated plasma volume; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; NYHA, New York Heart Association.

*N*: count; SD: standard deviation; Q1−Q3: 1^st^ and 3^rd^ quartiles.

###### 

Individual clinical characteristics

                             Baseline values   Blood level ranges during follow‐up                        
  ---- --- ---- ---- --- --- ----------------- ------------------------------------- --------- ---------- ----------
  01   M   68   Y    N   N   133/86            10                                    49--83    4.1--5.4   2.9--4.4
  02   M   68   N    Y   N   117/70            30                                    27--56    4.8--6.2   3.5--7.2
  03   M   60   N    Y   Y   112/64            35                                    47--92    3.1--7.0   4.2--6.0
  04   M   88   N    N   N   114/67            25                                    62--92    4.4--6.7   3.7--5.0
  05   M   78   Y    N   N   126/63            30                                    33--87    4.1--6.8   5.3--9.9
  06   M   66   Y    N   Y   95/63             25                                    56--92    3.9--7.4   2.6--4.6
  07   W   38   Y    N   Y   125/86            45                                    64--123   3.9--5.4   2.9--4.7
  08   W   79   Y    N   N   114/61            33                                    36--82    3.7--5.7   3.6--5.3
  09   M   72   Y    N   N   107/74            35                                    67--101   4.0--5.4   2.5--3.7
  10   M   71   N    N   Y   125/69            30                                    40--60    4.0--5.6   3.8--5.3
  12   M   76   Y    N   Y   125/67            35                                    38--53    4.4--5.7   3.7--4.6
  13   W   75   Y    N   N   145/89            20                                    25--62    3.9--6.0   3.0--4.6
  15   M   79   Y    N   N   96/51             40                                    40--63    3.6--6.0   5.0--7.6
  16   M   68   Y    N   N   MD                40                                    33--62    3.8--4.9   4.6--6.0
  18   W   84   MD   N   N   124/81            30                                    20--34    3.0--5.6   3.9--6.1

EF, ejection fraction; eGFR, estimated glomerular filtration rate; ePV, estimated plasma volume; ICD, implanted cardioverter defibrillator; MD, missing data; N, no; PM, pacemaker; SBP/DBP, systolic/diastolic blood pressure; Y, yes.

###### 

Individual treatments and events

+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| Patient | Baseline medications and daily doses (mg) | Drug changes    | Clinical event |                 |              |                   |                                                |
+:========+:==========================================+:================+:===============+:================+:=============+:==================+:===============================================+
| 01      | Ramipril 5                                | Bisoprolol 2.5  | Furosemide 120 | Eplerenone 12.5 | None         | D13: Biso 3.75    | None                                           |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D29: Biso 5       |                                                |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D30: Eple 25      |                                                |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D45: Eple 50      |                                                |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 02      | Ramipril 10                               | Celiprolol 200  | Furosemide 125 | Eplerenone 25   | Diffu‐K 600  | None              | D40: sudden death                              |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 03      | Ramipril 10                               | Bisoprolol 10   | Furosemide 375 | Spiro. 25       | Diffu‐K 4200 | D07: Furo 500     | None                                           |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D16: K+ 5400      |                                                |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D17: K+ 4200      |                                                |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D21: K+ decrease  |                                                |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D28: K+ 3600      |                                                |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D30: K+ 3000      |                                                |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D42: Furo 625     |                                                |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 04      | Candesartan 8                             | Bisoprolol 1.25 | Furosemide 40  | None            | None         | None              | D13: septic shock                              |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              |                   | D24: death                                     |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 05      | Perindopril 5                             | Bisoprolol 5    | Furosemide 40  | None            | Diffu‐K 1200 | None              | D27: bladder infection                         |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              |                   | D28: raised creatinine                         |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 06      | Candesartan 8                             | ---             | Furosemide 250 | Eplerenone 50   | Diffu‐K 7200 | None              | None                                           |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 07      | Perindopril 10                            | Bisoprolol 2.5  | Furosemide 40  | Spiro. 25       | None         | None              | D21: chest pain                                |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 08      | Perindopril 7.5                           | Bisoprolol 2.5  | Furosemide 40  | Spiro. 25       | None         | D01: Diffu‐K 600  | D48: viral infection of upper respiratorytract |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D20: stop Diffu‐K |                                                |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D20: Spiro 12.5   |                                                |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D29: Perin 2.5    |                                                |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D29: Biso 1.25    |                                                |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D29: Spir 25      |                                                |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 09      | Ramipril 5                                | Bisoprolol 7.5  | Furosemide 375 | None            | Diffu‐K 5400 | D03: Diffu‐K 3600 | None                                           |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D03: Biso 10      |                                                |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D03: Furo 125     |                                                |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 10      | Fosinopril 20                             | Bisoprolol 10   | Furosemide 125 | None            | Diffu‐K 1800 | D21: Furo 120     | None                                           |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D34: Furo 140     |                                                |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 12      | Ramipril 10                               | Bisoprolol 10   | Furosemide 40  | Eplerenone 50   | None         | None              | None                                           |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 13      | Fosinopril 20                             | ‐               | Furosemide 120 | Spiro. 25       | None         | None              | D45: stent (planned)                           |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              |                   | D52: dry cough                                 |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 15      | Ramipril 2.5                              | Bisoprolol 3.75 | Furosemide 60  | None            | Diffu‐K 1800 | None              |                                                |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 16      | Perindopril 5                             | Bisoprolol 10   | Furosemide 375 | Eplerenone 12.5 | Diffu‐K 1800 | D32: Diffu‐K 3000 | D22: ischemic acute pulmonary edema            |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D32: Rami 10      | D42: severe chest pain                         |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+
| 18      | Yes                                       | Yes             | Yes            | None            | None         | D05: Diffu‐K 600  | D36: dehydration                               |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D39: Bumetan. 2   | D41: nausea                                    |
|         |                                           |                 |                |                 |              |                   |                                                |
|         |                                           |                 |                |                 |              | D54: Fosi. 10     |                                                |
+---------+-------------------------------------------+-----------------+----------------+-----------------+--------------+-------------------+------------------------------------------------+

Yes: drug intake, no other specification.

![Mean kinetics in the 12 patients who completed the study. CKD‐EPI, Chronic Kidney Disease Epidemiology Collaboration; GFR, glomerular filtration rate; PV, plasma volume.](EHF2-7-1257-g001){#ehf212642-fig-0001}

###### 

Biological events during follow‐up

  -------------------------- --------------------------------------------------- ----------------- ----------------------------------------------- -------
  Parameter                  Number of[a](#ehf212642-note-0007){ref-type="fn"}   Mean ± SD         Median (Q1−Q3)                                  Range
  Potassium \>5.5 mmol/L     Episodes                                            1.7 ± 1.6         1.5 (0.5--0.5)                                  0--5
  Measurements per episode   4.4 ± 6.9                                           1.5 (0.5--0.5)    0--22                                           
  Potassium \>5.0 mmol/L     Episodes                                            2.2 ± 2.2         1.0 (1.0--1.0)                                  0--8
  Measurements per episode   9.1 ± 10.1                                          5.5 (2.5--2.5)    1[b](#ehf212642-note-0008){ref-type="fn"}--33   
  Potassium \<4.0 mmol/L     Episodes                                            1.9 ± 2.4         1.0 (0.0--0.0)                                  0--6
  Measurements per episode   3.7 ± 5.7                                           1.0 (0.0--0.0)    0--17                                           
  Potassium \<3.5 mmol/L     Episodes                                            0.5 ± 1.2         0.0 (0.0--0.0)                                  0--3
  Measurements per episode   0.7 ± 1.6                                           0.0 (0.0--0.0)    0--5                                            
  WRF \> 20%                 Episodes                                            1.3 ± 1.8         0.5 (0.0--0.0)                                  0--6
  Measurements per episode   5.3 ± 7.2                                           2.5 (0.0--0.0)    0--22                                           
  WRF \> 30%                 Episodes                                            0.7 ± 1.2         0.0 (0.0--0.0)                                  0--3
  Measurements per episode   2.4 ± 5.0                                           0.0 (0.0--0.0)    0--16                                           
  ePV \>5.5 mL/g Hb          Episodes                                            1.8 ± 2.6         0.0 (0.0--0.5)                                  0--7
  Measurements per episode   6.8 ± 11.6                                          0.0 (0.0--12.0)   0--37                                           
  ePV increase \>10%         Episodes                                            1.4 ± 1.5         1.0 (0.0--0.0)                                  0--5
  Measurements per episode   10.4 ± 9.1                                          12.0 (1.0--1.0)   0--30                                           
  ePV increase \>15%         Episodes                                            2.3 ± 2.4         1.5 (0.0--0.0)                                  0--6
  Measurements per episode   7.7 ± 8.0                                           8.0 (0.0--0.0)    0--25                                           
  -------------------------- --------------------------------------------------- ----------------- ----------------------------------------------- -------

Note that an episode with values \>x may include several shorter episodes with values y \> x, and conversely for values \<x and y with y \< x. For instance, the mean number of episodes with ePV increases \>10% (1.4 ± 1.5) was lower than for increases \>15% (2.3 ± 2.4), although the mean number of measurements per episode was higher (10.4 ± 9.1 vs. 7.7 ± 8.0).

ePV, estimated plasma volume; WRF, worsening renal function from baseline.

12 complete observations, excluding three premature (two deaths and one hospitalization for ischaemic acute pulmonary oedema) and five consent withdrawals.

One patient had only one 1‐day hyperkalaemia \>5.5 mmol/L.

At the individual level ([*Data S1*](#ehf212642-supitem-0001){ref-type="supplementary-material"}), relevant and consistent profiles (e.g. persistent and/or recurrent dyskalaemia, WRF, recongestion, or decongestion patterns) were easily identified. For instance, Patient \#2 (who suddenly died at Day 40), Patients \#6 and \#13 were chronically hyperkalaemic and displayed sustained trends toward worsening renal function and recongestion, without any recorded change in cardiovascular medications. Before being rehospitalized for an acute pulmonary oedema of ischaemic origin, Patient \#16 had a decrease in ePV and became hypokalaemic, with a transient WRF. When considering congestion separately, six patients presented ePV \>5.5 mL/g Hb at inclusion (Patients \#05 and \#15: permanently raised ePV; Patient \#16: ePV oscillating at around the 5.5‐threshold value), indicative of post‐discharge residual congestion, and/or ePV \>5.5 mL/g Hb during follow‐up. Patient \#02 had an ePV \<5.5 at inclusion, which continued to increase steadily until sudden death, which occurred in conjunction with massive leg oedema. Patient \#03 had an ePV close to the threshold, with short occasional excursions above 5.5, while Patient \#18 had a slow increase in ePV during follow‐up, with values oscillating around 5.5 after Day 28. Of note, this latter Patient \# 18 was nevertheless documented as "clinically dehydrated" by the treating physician at Day 36, concomitant with an obvious decrease in ePV, a WRF, and hypokalaemia.

Conclusions {#ehf212642-sec-0008}
===========

To the best of our knowledge, this is the first attempt of a daily home monitoring of blood potassium, eGFR, and ePV in HFrEF patients within the vulnerable post‐discharge phase. Despite its small sample size and related limitation, such home monitoring study was already able to capture a substantial number of clinically relevant cardiorenal and electrolytic changes which are otherwise undiagnosed in routine daily practice with no monitoring.[14](#ehf212642-bib-0014){ref-type="ref"}, [15](#ehf212642-bib-0015){ref-type="ref"} Additionally, given that (i) undiagnosed residual congestion is a major driver of post‐discharge early readmission[2](#ehf212642-bib-0002){ref-type="ref"}; (ii) excessive decongestion and use of diuretic therapy is associated with dehydration, hypotension, WRF, and poor prognosis[16](#ehf212642-bib-0016){ref-type="ref"}; (iii) dyskalaemia is associated with poor outcome[17](#ehf212642-bib-0017){ref-type="ref"}; and hyperkalaemia and WRF are the main reasons for the underuse, underdosing and frequent discontinuation of RAASi, and mineralocorticoid antagonists[18](#ehf212642-bib-0018){ref-type="ref"}; and (iv) use of the newly available potassium binders warrants proper biological monitoring,[19](#ehf212642-bib-0019){ref-type="ref"} we believe that concomitant monitoring of plasma volume, blood potassium, and renal function is a relevant strategy for assessing congestion and the delicate cardiorenal balance.[20](#ehf212642-bib-0020){ref-type="ref"} Plasma volume, blood potassium, and renal function are potentially the most clinically actionable variables for the dynamic optimization of diuretic therapy and of life‐saving RAASi therapy.

The ongoing HERMES HF study (NCT04050904) is currently assessing the short‐term feasibility and safety of such a monitoring strategy, complemented by a decision support system ("ExpHeart"), and generating recommendations based on ESC clinical guidelines (CardioRenal ExpHeart) in patients discharged after an episode of worsening HFrEF.
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